Mesoblast
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
L 38 55 Collins St, Melbourne, Victoria,...Phone Number
+61 396396036Website
www.mesoblast.comRevenue
$5.9 MillionStock Symbol
MSBIndustry
ZI Rank: 4
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
4
3
9
6
4
4
About Mesoblast
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.Explore more
Mesoblast Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mesoblast your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Mesoblast has new funding data
Check out if Mesoblast is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Mesoblast
Earning: See what the market has to say on Mesoblast recently announced quarterly report
Click to see if Mesoblast had a recent Job posting/layoffs
Mesoblast, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Mesoblast launches new products
Check if Mesoblast has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Mesoblast
Compare insights from companies similar to Mesoblast, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mesoblast is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Mesoblast is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Mesoblast.
Mesoblast financials insights
Gather financial insights about Mesoblast, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$68.3M
2017
Share Placement
$40M
2018
Debt
$75M
2019
Share Placement
$51M
2020
Share Placement
$90M
2021
Corporate Investment
$110M
2025
Share Placement
$260M
Stock/Share Issuance
$50M
Mesoblast Tech Stack
A closer look at the technologies used by Mesoblast
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations, Manufacturing Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Sales
Mesoblast News & Media
Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes TreatmentMesoblast Financial Results and Corporate Update Webcast
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2026.Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with the inflammatory condition of degenerative disc disease. The major milestone was achieved with 350 patients randomized and treated with either an intra-diMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases
Read more news
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mesoblast
Sign Up For FreeTo access detailed company insights
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.... Read More
